Integra LifeSciences (IART) Tops Q3 EPS by 1c, Updates FY Guidance

Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.75, $0.01 better than the analyst estimate of $0.74. Revenue for the quarter came in at $226.4 million versus the consensus estimate of $224.08 million.

Integra LifeSciences sees FY2015 EPS of $3.05-$3.10, versus the consensus of $3.06. Integra LifeSciences sees FY2015 revenue of $878-885 million, versus the consensus of $880.3 million.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Oxford Industries (OXM) Tops Q1 EPS by 12c; Offers Outlook
• Oracle (ORCL) Tops Q4 EPS by 16c, Offers Guidance